Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Blood (2022) 140 (Supplement 1): 2310–2312.

https://doi.org/10.1182/blood-2022-156789

Published: 2022

Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten

Blood (2022) 140 (Supplement 1): 12784–12785.

https://doi.org/10.1182/blood-2022-164650

Published: 2022

Journal Articles

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Francisco Llamas-Gutierrez, Emmanuel Itti, Cedric Menard, Yassine Al-Tabaa, Clement Bailly, Marie-Helene Delfau, Camille Laurent, Francois Lemonnier

Blood (2022) 140 (Supplement 1): 410–411.

https://doi.org/10.1182/blood-2022-156626

Published: 2022

Journal Articles

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Louise Roulin, Elsa Poullot, Paul Blanc-Durand, Cyrielle Robe, Francois Lemonnier, Fabien Le Bras, Romain Gounot, Karim Belhadj, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Sebastien Mule, Christiane Copie Bergman, Thierry Molina, Marie Helene Delfau Larue, Emmanuel Itti, Philippe Gaulard, Corinne Haioun

Blood (2021) 138 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2021-152627

Published: 2021

Journal Articles

Single-Cell and Spatial Analyses Characterize Distinct Subsets of Malignant T Cells in Angioimmunoblastic T Cell Lymphoma

Francois Lemonnier, Chuang Dong, Bruno Tesson, Laurine Gil, Noudjoud Attaf, Diana-Laure Mboumba, Philippe Gaulard, Pierre Milpied

Blood (2021) 138 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2021-147246

Published: 2021

Journal Articles

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Charles Herbaux, Stéphanie Poulain, Damien Roos-Weil, Jacques-Olivier Bay, Yann Guillermin, Francois Lemonnier, Kamel Laribi, Sorin Visanica, Jerome Moreaux, Hugo Gonzalez, Maxime Jullien, Abderrazak El Yamani, Houria Debarri, Sophie Godet, Franck Morschhauser, Olivier Tournilhac, Matthew S. Davids, Loic Ysebaert

Blood (2021) 138 (Supplement 1): 1201.

https://doi.org/10.1182/blood-2021-149228

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Blood (2020) 135 (5): 360–370.

https://doi.org/10.1182/blood.2019001904

Published: 2020

Includes: Supplemental data

Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD

Blood (2019) 134 (Supplement_1): 4115.

https://doi.org/10.1182/blood-2019-124143

Published: 2019

Journal Articles

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Blood (2019) 134 (Supplement_1): 4122.

https://doi.org/10.1182/blood-2019-123259

Published: 2019

Journal Articles

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Blood (2019) 133 (15): 1664–1676.

https://doi.org/10.1182/blood-2018-09-872549

Published: 2019

Includes: Supplemental data

Journal Articles

Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study

Blood (2018) 132 (Supplement 1): 999.

https://doi.org/10.1182/blood-2018-99-110354

Published: 2018

Journal Articles

Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring

Sophie Broutin, PhD PharmD, Francois Lemonnier, MD PhD, Aurélie Dupuy, PhD, Julia Delahousse, Virginie Fataccioli, PhD, Vincent Ribrag, MD, Violaine Safar, MD, Laura Pelletier, Cyrielle Robe, Herve Tilly, MD, Anne Ségolène Cottereau, MD, Céline Bossard, MD, Laurence de Leval, MD, Marie-Helene Delfau, MD, Corinne Haioun, MD, Angelo Paci, PharmD, PhD, Philippe Gaulard, MD

Blood (2018) 132 (Supplement 1): 2898.

https://doi.org/10.1182/blood-2018-99-115893

Published: 2018

Journal Articles

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

François Lemonnier, Jehan Dupuis, Pierre Sujobert, Olivier Tournillhac, Morgane Cheminant, Clémentine Sarkozy, Laura Pelletier, Ambroise Marçais, Cyrielle Robe, Virginie Fataccioli, Corinne Haioun, Olivier Hermine, Philippe Gaulard, Richard Delarue

Blood (2018) 132 (21): 2305–2309.

https://doi.org/10.1182/blood-2018-04-840538

Published: 2018

Includes: Supplemental data

Journal Articles

Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas

Richard Delarue, MD, Jehan Dupuis, MD, Pierre Sujobert, MD PhD, Sarah Barbieux, MD, Ambroise Marçais, MD, Olivier Tournilhac, MD PhD, Florence Lachenal, MD, Morgane Cheminant, MD, Clementine Sarkozy, MD, Virginie Fataccioli, PhD, Franck Morschhauser, Olivier Hermine, MD PhD, Corinne Haioun, MD PhD, Philippe Gaulard, MD PhD, Francois Lemonnier, MD PhD

Blood (2016) 128 (22): 4164.

https://doi.org/10.1182/blood.V128.22.4164.4164

Published: 2016

Journal Articles

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas

Blood (2016) 128 (11): 1490–1502.

https://doi.org/10.1182/blood-2016-02-698977

Published: 2016

Includes: Supplemental data

Journal Articles

Bronchiolitis Obliterans Occurring after Allogenic Hematopoietic Stem Cell Transplant: Comparison of Outcome Between Patients Equipped or Not with Home Spirometry Monitoring

Clémence Loiseau, Francois Lemonnier, MD, Odile Randrianarivelo, MD, Raphael Itzykson, MDPhD, Marie Hélène Becquemin, MD, Stephanie Nguyen Quoc, MDPhD, Madalina Uzunov, MD, Emilie Catherinot, MD, Elisabeth Rivaud, MD, Laurent Sutton, MD, Jean-Paul Vernant, MD, Louis Jean Couderc, MD, Nathalie Dhedin, MD

Blood (2015) 126 (23): 3161.

https://doi.org/10.1182/blood.V126.23.3161.3161

Published: 2015

Journal Articles

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Fabrice Jardin, MD PhD, Anais Pujals, PhD, Laura Pelletier, PhD, Elodie Bohers, PhD, Vincent Camus, Sylvain Mareschal, Sydney Dubois, Marlène Ochman, MD, Francois Lemonnier, MD, Pierre-Julien Viailly, Philippe Bertrand, PhD, Catherine Maingonnat, Alexandra Traverse-Glehen, Philippe Gaulard, MD PhD, Diane Damotte, MD PhD, Richard Delarue, MD, Corinne Haioun, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD, Christian Argueta, PhD, Gilles Andre Salles, MD PhD, Jean-Philippe Jais, MD PhD, Martin Figeac, PhD, Christiane Copie-Bergman, MD PhD, Thierry Molina, Jean-Michel Picquenot, PhD, Marie Cornic, Thierry Fest, MD PhD, Noel Milpied, Emilie Lemasle, MD, Aspasia Stamatoullas, MD, Peter Moeller, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Christer Sundstrom, MD PhD, Christian Bastard, MD PhD, Hervé Tilly, MD PhD, Karen Leroy, MD PhD

Blood (2015) 126 (23): 129.

https://doi.org/10.1182/blood.V126.23.129.129

Published: 2015

NARROW

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Single-Cell and Spatial Analyses Characterize Distinct Subsets of Malignant T Cells in Angioimmunoblastic T Cell Lymphoma

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study

Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas

Bronchiolitis Obliterans Occurring after Allogenic Hematopoietic Stem Cell Transplant: Comparison of Outcome Between Patients Equipped or Not with Home Spirometry Monitoring

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only